In vitro activity and preliminary toxicity of various diamidine compounds against Trypanosoma evansi.

Vet Parasitol

Parasite Chemotherapy, Department of Medical Parasitology and Infection Biology, Swiss Tropical Institute, Socinstrasse 57, 4002 Basel, Switzerland.

Published: May 2010

Trypanosoma evansi is an animal pathogenic protozoan, causing a wasting disease called Surra, which is broadly distributed in a wide range of mammalian hosts. Chemotherapy is the most efficient control method, which depends on four drugs. Unfortunately, with the appearance of resistance to these drugs, their effective use is threatened, emphasising a need to find new drugs. Diamidines bind to the minor groove of DNA at AT-rich sites and exert their anti-trypanosomal activity by inhibiting one or more DNA dependent enzymes or by directly impeding the transcription process. In total, 67 novel diamidine compounds were tested in vitro to determine activity against an animal pathogenic Chinese kinetoplastic T. evansi strain. In comparison, a human pathogenic Trypanosoma brucei rhodesiense strain and a P2 transporter knock out of a Trypanosoma brucei brucei strain were also tested. All diamidine compounds tested in this study against T. evansi produced inhibitory concentration (IC(50)) values below 50 nM. The results demonstrate that these compounds are highly active against T. evansi in vitro. In addition, preliminary in vivo toxicity tests were performed on all 67 diamidines with 69% of the compounds showing no acute toxicity at an intra-peritoneal dose of 100mg/kg.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vetpar.2010.01.019DOI Listing

Publication Analysis

Top Keywords

diamidine compounds
12
trypanosoma evansi
8
animal pathogenic
8
compounds tested
8
trypanosoma brucei
8
compounds
5
evansi
5
vitro activity
4
activity preliminary
4
preliminary toxicity
4

Similar Publications

Transforming the chemotherapy of human African trypanosomiasis.

Clin Microbiol Rev

January 2025

School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.

SUMMARYPrior to 2019, when the orally available drug fexinidazole began its clinical use, the treatment of human African trypanosomiasis (HAT) was complex and unsatisfactory for many reasons. Two sub-species of the parasite are responsible for HAT, namely the rhodesiense form found in East and Southern Africa and the gambiense form found in Central and West Africa. Diseases caused by both forms manifest in two stages: stage 1 before and stage 2 after central nervous system involvement.

View Article and Find Full Text PDF

Enhancing Antileishmanial Activity of Amidoxime-Based Compounds Bearing a 4,5-Dihydrofuran Scaffold: In Vitro Screening Against .

Molecules

November 2024

Aix Marseille Univ, CNRS, ICR UMR 7273, Equipe Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, 27 Boulevard Jean Moulin, CS30064, CEDEX 05, 13385 Marseille, France.

Article Synopsis
  • - Leishmaniasis, caused by a protozoan, has treatment gaps, leading to the development of new amidoxime derivatives aimed at improving antileishmanial activity.
  • - Twelve new compounds were created by modifying a previous hit, using a three-step synthesis process that included cyclization, amidation, and reaction with hydroxylamine.
  • - Three specific derivatives showed promising in vitro toxicity-activity results, with high selectivity indices (SI) against the parasite, indicating they could potentially be more effective and less toxic than existing treatments like Pentamidine.
View Article and Find Full Text PDF

Pharmacologic Blockade of a Pioneer Transcription Factor.

Cancer Res

December 2024

Center for Precision Environmental Health and Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.

Cancers frequently co-opt lineage-specific transcription factors (TF) utilized in normal development to sustain proliferation. However, the effects of these TFs on tumor development depend considerably on where in the genome they bind. A new article by Taylor and colleagues expands on previously developed diamidine compounds that obstruct the DNA binding sites of the pioneer TF PU.

View Article and Find Full Text PDF

The diversity of AMPA receptor inhibition mechanisms among amidine-containing compounds.

Front Pharmacol

October 2024

Laboratory for the Research of the Mechanisms of Regulation and Compensation of Nervous System Excitability Pathologies, I.M. Sechenov Institute of Evolutionary Physiology and Biochemistry RAS, Saint Petersburg, Russia.

Amidine-containing compounds are primarily known as antiprotozoal agents (pentamidine, diminazene, furamidine) or as serine protease inhibitors (nafamostat, sepimostat, camostat, gabexate). DAPI is widely recognized as a fluorescent DNA stain. Recently, it has been shown that these compounds also act as NMDA receptor inhibitors.

View Article and Find Full Text PDF
Article Synopsis
  • Quinoline-urea-benzothiazole hybrid compounds showed promising anti-parasitic activities against the 3D7 chloroquine-sensitive strain with effective concentrations ranging from 0.33 to 0.97 μM.
  • Many hybrids performed comparably to chloroquine in inhibiting β-haematin formation, with two compounds showing slightly better efficacy than chloroquine.
  • Molecular docking studies indicated that some compounds had higher binding energies than known drugs like chloroquine and pentamidine, and stability was confirmed through 100 ns simulations, indicating potential for effective enzyme targeting.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!